生物技术公司Viking Therapeutics(VKTX.US)周一盘前股价大涨24%,此前该公司公布了令人鼓舞的早期研究结果:其实验性口服减肥药物VK2735在高剂量下可使患者在28天内平均减轻8.2%体重。
这一数据超出了分析师的预期,引发市场关注,因为与注射减肥药相比,该药物以方便服用的药丸形式出现,可避免许多患者对注射治疗的犹豫。分析师认为,如果数据在后续大规模试验中得到验证,VK2735将在庞大且不断增长的减肥药物市场上占据有利地位。
Viking公司计划在2024年底之前开始VK2735的二期临床试验。该药物目前的主要竞争对手是礼来和诺和诺德旗下的减肥针剂药物,两家公司也在开发基于口服的新一代肥胖症药物。投资者认为,作为首批实现简单口服的减肥药之一,Viking的药物有望在未来较长一段时间内保持独特优势。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.